The Role of Statin Therapy for Primary Prevention: What is the Evidence?
- 256 Downloads
Almost one third of annual worldwide mortality is attributed to cardiovascular disease (CVD), making it the leading cause of global death. Dyslipidemia is a well-established risk factor for CVD and plays a pivotal role in the pathogenesis of atherosclerosis. Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and lower low-density lipoprotein cholesterol, have emerged as the most effective therapy to date against atherothrombotic CVD. Although their role in secondary prevention of CVD is undisputed, it remains a topic for debate as to how widely they should be used for primary prevention. The Framingham Risk Score and the National Cholesterol Education Program Adult Treatment Panel III guidelines are the cornerstones for the current guidelines for primary prevention statin therapy. Although these guidelines serve as help to evaluate cardiovascular risk and effectively identify many patients who will benefit from statin therapy, there is a growing population of “intermediate-risk” patients who may be undertreated. Additional noninvasive tests may complement the traditional risk scores, potentially expanding the indications for statins.
KeywordsStatins Primary prevention Evidence
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.The global burden of disease: 2004 update. World Health Organization; 2008.Google Scholar
- 12.Brown BG, Zhao XQ, Sacco DEGoogle Scholar
- 16.National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143.Google Scholar
- 22.Sever P, Dahlof B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOTT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–58.PubMedCrossRefGoogle Scholar
- 27.• Hsia J, MacFadyen J, Monyak J, Ridker P. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dL with rosuvastatin. The JUPITER Trial. JACC. 2011;57:1666–75. This was a subgroup analysis from the JUPITER trial that showed that it was safe to attain LDL cholesterol levels <50 mg/dL and that these patients had the greatest relative risk reduction compared with placebo. PubMedGoogle Scholar
- 28.Food and Drug Administration. Highlights of prescribing information: crestor tablets. Available at: http://www.accessdata.fda.cov/drugsatfda_docs/label2010/021366s016lbl.pdf. Accessed March 2011.
- 29.Morrissey R, Diamond G, Kaul S. The JUPITER trial: myth or reality. Curr Atherosclerosis Rep. 2011. Published ahead of print online.Google Scholar
- 36.Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Lib. 2011;8:1–58.Google Scholar
- 37.Grammer TB. Are statins really useless in “primary prevention”? recent Cochrane meta-analysis revisited. Int J Clin Pharmacol Therapeut. 2011;49:293–6.Google Scholar
- 38.Fabbian F, De Giorgi A, et al. Evidence-based statin prescription for carediovascular protection in renal impairment. Clin Exp Nephrol. 2011, published on-line.Google Scholar
- 42.Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors for people with chronic kidney disease not requiring dialysis. Review. Cochrane Lib. 2009;3:1–65.Google Scholar
- 44.• Baigent C, Landray M and the SHARP investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. The Lancet. 2011;377:2181–92. This is a large randomized trial that highlighted the benefit of statin therapy for primary prevention in patients with chronic kidney disease. It included patients with end-stage renal disease on dialysis. PubMedCrossRefGoogle Scholar
- 49.Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108:2154–69.PubMedCrossRefGoogle Scholar